
New Era Helium Receives Approval for Approximately 120 Miles of Rights-of-Way to Support Midstream Business Unit and Responsibly Sourced Gas Initiatives within the Pecos Slope, Permian Basin
New Era Helium, Inc. (Nasdaq: NEHC) ('NEH' or the 'Company'), an exploration and production (E&P) company sourcing helium from natural gas reserves in the Permian Basin, today announced it will commence its infrastructure buildout within the Pecos Slope Field within the next two weeks as it has secured approval for approximately 120 miles of Rights-of-Way (ROW) in collaboration with the U.S. Department of the Interior's Bureau of Land Management (BLM) Pecos District Office. This major milestone supports the Company's efforts focused on delivering Responsibly Sourced Gas (RSG) and Responsibly Sourced Helium (RSH™).
NEH is advancing plans to replace the aging gathering infrastructure originally installed in the early 1980s, which currently poses significant inefficiencies and environmental concerns. The legacy system, owned and operated by a third party, experiences approximately 25% Field Loss and Unaccounted For (FL&U) gas, leading to substantial financial and environmental impacts. For example, NEH's current daily production of approximately 4,000 Mcfpd, combined with a 25% loss, results in approximately 30,000 Mcf of monthly vented methane ('Ch4') equivalent to the CO₂ emissions produced by approximately 37,905 passenger vehicles per year. These estimates reflect the Company's production and does not take into account the remaining volumes that are gathered and treated by this aging system each day.
With this new infrastructure, NEH Midstream LLC, New Era Helium's wholly owned subsidiary, aims to minimize methane emissions, positioning its production for RSG certification and enhancing the value of its helium as RSH™, a designation trademarked by the Company. Since 95% of the world's helium is produced alongside natural gas, NEH sees a major opportunity to lead the industry in both reducing emissions alongside creating Methane Performance Certificates (MPCs), similar to carbon credits.
NEH has been granted an initial six-month window by the BLM to temporarily shut in its wells during the installation of the new gathering system, should it elect to utilize this option. The Company is also working closely with the New Mexico State Land Office to ensure alignment with regulatory standards. Expected regulatory updates within the next 90 days could further streamline pipeline installations, potentially reducing project costs and timelines.
In parallel, NEH is finalizing design optimizations with its plant manufacturer, Arjae Design Solutions, focusing on enhancing helium purity at the plant's tailgate. The Company remains committed to begin helium sales in late Q4 2025, pending timely construction progress. Additional updates will be provided in the coming weeks.
E. Will Gray II, CEO of New Era Helium, Inc., commented: 'Reducing fugitive methane emissions is critical to our environmental stewardship goals and supports our broader mission to deliver responsibly sourced products. Methane has a significantly higher global warming potential than CO₂ and modernizing the Pecos Slope Field's infrastructure will not only improve operational efficiency but also greatly reduce the region's carbon footprint, located within southeastern New Mexico portion of the Permian Basin, while positioning us to meet evolving regulatory standards and enhance long-term value for our stakeholders.'
About New Era Helium, Inc.
New Era Helium, Inc. is an exploration and production company that sources helium produced in association with the production of natural gas reserves in North America. The company currently owns and operates over 137,000 acres in Southeast New Mexico and has over 1.5 billion cubic feet of proved and probable helium reserves. For more information, visit www.newerahelium.com. Follow New Era Helium on LinkedIn and X.
Cautionary Note Regarding Forward-Looking Statements
This press release contains 'forward-looking statements.' Forward-looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) our ability to effectively operate our business segments; (b) our ability to manage our research, development, expansion, growth and operating expenses; (c) our ability to evaluate and measure our business, prospects and performance metrics; (d) our ability to compete, directly and indirectly, and succeed in a highly competitive and evolving industry; (e) our ability to respond and adapt to changes in technology and customer behavior; (f) our ability to protect our intellectual property and to develop, maintain and enhance a strong brand; and (g) other factors (including the risks contained in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250429921151/en/
CONTACT: Investor and Media Contact:
Investor Relations
[email protected]
Tel +1 475 477 9401
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: OIL/GAS ENERGY
SOURCE: New Era Helium, Inc.
Copyright Business Wire 2025.
PUB: 04/29/2025 07:30 AM/DISC: 04/29/2025 07:29 AM
http://www.businesswire.com/news/home/20250429921151/en

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
a minute ago
- Wall Street Journal
Heard on the Street Friday Recap: European Negotiation
The S&P 500 closed at a record for the fifth session in a row. The S&P advanced 0.4% Friday and the Nasdaq Composite rose 0.2%, both hitting all-time highs. The Dow Jones Industrial Average added 208 points. Calmer Federal Reserve politics boosted the dollar. After a visit to the Fed's headquarters renovations, President Trump said he didn't think it was necessary to fire Chair Jerome Powell. The WSJ Dollar Index rose about 0.3%, while gold fell.


Business Insider
9 minutes ago
- Business Insider
Pinnacle Financial Partners (PNFP) Receives a Buy from Barclays
Barclays analyst Jared Shaw maintained a Buy rating on Pinnacle Financial Partners on July 25 and set a price target of $125.00. The company's shares closed last Friday at $91.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Shaw is a 3-star analyst with an average return of 1.1% and a 53.28% success rate. Shaw covers the Financial sector, focusing on stocks such as UMB Financial, Cadence Bank, and BankUnited. In addition to Barclays, Pinnacle Financial Partners also received a Buy from Truist Financial's John McDonald CFA in a report issued on July 25. However, on July 26, TR | OpenAI – 4o downgraded Pinnacle Financial Partners (NASDAQ: PNFP) to a Hold. The company has a one-year high of $131.91 and a one-year low of $81.57. Currently, Pinnacle Financial Partners has an average volume of 673.6K. Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PNFP in relation to earlier this year. Most recently, in May 2025, Robert A. Jr. Mccabe, the CHAIRMAN of PNFP sold 50,589.00 shares for a total of $5,326,515.81.


Business Wire
30 minutes ago
- Business Wire
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice ® platforms—including RenMab™ (fully human antibody), RenLite ® (common light chain), RenNano ® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice ® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice ® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit